Design and discovery of new classes of anticancer agents with unique mechanisms of
action is an urgent medical need. During the past several years, a series of salicylhydrazide class of
compounds were reported to possess remarkable potency in a large panel of cancer cell lines from
different tumor origins. In particular, the optimized lead compound, SC144, was further investigated
and selected as a valuable drug candidate endowed with favorable pharmacokinetic and antiproliferative
properties in various in vitro and in vivo xenograft models. This lead compound is active
in cells resistant to conventional chemotherapies, synergistic with several standard-of-care drugs, and possesses an unique
mechanism acting through the inhibition of the gp130-STAT3-survivin axis. Because of this novel mechanism, clinical
development of SC144 will provide new therapeutic options for diverse cancers.
Keywords: Anticancer agents, cytotoxicity, gp130, hydrazides, IL-24, pyrroloquinoxaline, survivin.
Rights & PermissionsPrintExport